Skip to main content

Table 1 Clinical trials using gene expression analysis

From: Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy

Sponsor

Principal investigator, centre

Disease, application

European Organization for Research and Treatment of Cancer

The Netherlands Cancer Institute, Amsterdam, The Netherlands

Breast cancer, comparing van't Veer and van de Vijver prognostic signature to St Gallen criteria

Avon Foundation

Daniel Haber, Massachusetts General Hospital, Boston, MA, USA

Breast cancer, validating van't Veer and van de Vijver prognostic signature

Breast Cancer Research Foundation, Millennium Pharmaceuticals

Lajos Pusztai, Anderson Cancer Center, Houston, TX, USA

Breast cancer, validating own signature for predicting drug response

Millennium Pharmaceuticals

Kenneth Anderson, Dana-Farber Cancer Center, Boston, MA, USA

Multiple myeloma, validating own signature for response to Velcade

National Cancer Institute

Jenny Chang, Baylor College of Medicine, Houston, TX, USA

Breast cancer, validating own 90-gene prognostic signature

  1. Table adapted from Branca, M. (2003), Science Vol. 300, p. 238